Longitudinal study of cognitive function in glioma patients treated with modern radiotherapy techniques and standard chemotherapy
(2020) In Acta Oncologica 59(9). p.1091-1097- Abstract
Introduction: Cognitive function is an important outcome measure in patients with brain tumor, providing information about the patient’s clinical situation, treatment effects and possible progressive disease. The aim of this longitudinal study was to evaluate effects of the currently used radiation and chemotherapy treatment on cognitive function and to investigate associations between cognitive function at baseline and progression as well as overall survival. Methods: 32 patients newly diagnosed with malignant glioma were evaluated at baseline with CNS Vital Signs (CNS-VS), a computerized standardized neuropsychological test battery, prior to arc-based radiotherapy and concomitant chemotherapy with Temozolomide. CNS-VS measures the... (More)
Introduction: Cognitive function is an important outcome measure in patients with brain tumor, providing information about the patient’s clinical situation, treatment effects and possible progressive disease. The aim of this longitudinal study was to evaluate effects of the currently used radiation and chemotherapy treatment on cognitive function and to investigate associations between cognitive function at baseline and progression as well as overall survival. Methods: 32 patients newly diagnosed with malignant glioma were evaluated at baseline with CNS Vital Signs (CNS-VS), a computerized standardized neuropsychological test battery, prior to arc-based radiotherapy and concomitant chemotherapy with Temozolomide. CNS-VS measures the cognitive functions known to be affected in patients with brain tumor, covering nine cognitive domains. Follow-up cognitive evaluations were performed in 26 patients after 3.5 months and in 13 patients 1 year after treatment start. Results: Overall cognitive scores were lower in the studied patient cohort at baseline compared to standardized domain scores. At 3.5 months follow-up cognitive functioning was slightly decreased, but only in 1/9 cognitive domains–visual memory–where significant changes were found compared to baseline test results. Similarly, at 12 months follow-up no significant changes in cognitive test results were seen compared to baseline examination, except for a decrease in the visual memory domain. In relation to early progression, the most significant cognitive deficits were dysfunctional visual memory and low executive functioning at baseline. Low executive function at baseline correlated most significantly with shorter overall survival. Conclusion: The present study suggests that the currently used arc-based radiotherapy and chemotherapy might affect cognitive function less negatively than previously described during treatment and in the first year after treatment in malignant glioma patients. In general, a high cognitive test score at baseline was associated with longer time to progression and with longer survival.
(Less)
- author
- Rydelius, Anna LU ; Lätt, Jimmy LU ; Kinhult, Sara LU ; Engelholm, Silke ; Van Westen, Danielle LU ; Pihlsgård, Mats LU ; Bengzon, Johan LU ; Sundgren, Pia C. LU and Lilja, Åsa LU
- organization
-
- LUCC: Lund University Cancer Centre
- Neuroradiology (research group)
- MR Physics (research group)
- Tumor microenvironment
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- Geriatrics (research group)
- Neurosurgery
- StemTherapy: National Initiative on Stem Cells for Regenerative Therapy
- Stem Cell Center
- Lund University Bioimaging Center
- Diagnostic Radiology, (Lund)
- publishing date
- 2020-06-17
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Oncologica
- volume
- 59
- issue
- 9
- pages
- 7 pages
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:32847475
- scopus:85087022774
- ISSN
- 0284-186X
- DOI
- 10.1080/0284186X.2020.1778181
- language
- English
- LU publication?
- yes
- id
- 9475bff0-f89d-42cf-bf85-c8559f8b7cd0
- date added to LUP
- 2020-07-10 10:57:26
- date last changed
- 2024-04-17 12:17:24
@article{9475bff0-f89d-42cf-bf85-c8559f8b7cd0, abstract = {{<p>Introduction: Cognitive function is an important outcome measure in patients with brain tumor, providing information about the patient’s clinical situation, treatment effects and possible progressive disease. The aim of this longitudinal study was to evaluate effects of the currently used radiation and chemotherapy treatment on cognitive function and to investigate associations between cognitive function at baseline and progression as well as overall survival. Methods: 32 patients newly diagnosed with malignant glioma were evaluated at baseline with CNS Vital Signs (CNS-VS), a computerized standardized neuropsychological test battery, prior to arc-based radiotherapy and concomitant chemotherapy with Temozolomide. CNS-VS measures the cognitive functions known to be affected in patients with brain tumor, covering nine cognitive domains. Follow-up cognitive evaluations were performed in 26 patients after 3.5 months and in 13 patients 1 year after treatment start. Results: Overall cognitive scores were lower in the studied patient cohort at baseline compared to standardized domain scores. At 3.5 months follow-up cognitive functioning was slightly decreased, but only in 1/9 cognitive domains–visual memory–where significant changes were found compared to baseline test results. Similarly, at 12 months follow-up no significant changes in cognitive test results were seen compared to baseline examination, except for a decrease in the visual memory domain. In relation to early progression, the most significant cognitive deficits were dysfunctional visual memory and low executive functioning at baseline. Low executive function at baseline correlated most significantly with shorter overall survival. Conclusion: The present study suggests that the currently used arc-based radiotherapy and chemotherapy might affect cognitive function less negatively than previously described during treatment and in the first year after treatment in malignant glioma patients. In general, a high cognitive test score at baseline was associated with longer time to progression and with longer survival.</p>}}, author = {{Rydelius, Anna and Lätt, Jimmy and Kinhult, Sara and Engelholm, Silke and Van Westen, Danielle and Pihlsgård, Mats and Bengzon, Johan and Sundgren, Pia C. and Lilja, Åsa}}, issn = {{0284-186X}}, language = {{eng}}, month = {{06}}, number = {{9}}, pages = {{1091--1097}}, publisher = {{Taylor & Francis}}, series = {{Acta Oncologica}}, title = {{Longitudinal study of cognitive function in glioma patients treated with modern radiotherapy techniques and standard chemotherapy}}, url = {{http://dx.doi.org/10.1080/0284186X.2020.1778181}}, doi = {{10.1080/0284186X.2020.1778181}}, volume = {{59}}, year = {{2020}}, }